Search Results - "Bosch‐Barrera, Joaquim"

Refine Results
  1. 1

    Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype by Cuyàs, Elisabet, Fernández-Arroyo, Salvador, Corominas-Faja, Bruna, Rodríguez-Gallego, Esther, Bosch-Barrera, Joaquim, Martin-Castillo, Begoña, De Llorens, Rafael, Joven, Jorge, Menendez, Javier A

    Published in Oncotarget (20-05-2015)
    “…Metabolic flexibility might be particularly constrained in tumors bearing mutations in isocitrate dehydrogenase 1 (IDH1) leading to the production of the…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Metformin: multi-faceted protection against cancer by Del Barco, Sonia, Vazquez-Martin, Alejandro, Cufí, Sílvia, Oliveras-Ferraros, Cristina, Bosch-Barrera, Joaquim, Joven, Jorge, Martin-Castillo, Begoña, Menendez, Javier A

    Published in Oncotarget (01-12-2011)
    “…The biguanide metformin, a widely used drug for the treatment of type 2 diabetes, may exert cancer chemopreventive effects by suppressing the transformative…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells by Verdura, Sara, Encinar, José Antonio, Fernández-Arroyo, Salvador, Joven, Jorge, Cuyàs, Elisabet, Bosch-Barrera, Joaquim, Menendez, Javier A

    “…The third-generation anaplastic lymphoma tyrosine kinase inhibitor (ALK-TKI) lorlatinib has a unique side effect profile that includes hypercholesteremia and…”
    Get full text
    Journal Article
  7. 7

    AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models by Polonio-Alcalá, Emma, Porta, Rut, Ruiz-Martínez, Santiago, Vásquez-Dongo, Carmen, Relat, Joana, Bosch-Barrera, Joaquim, Ciurana, Joaquim, Puig, Teresa

    Published in Biomedicine & pharmacotherapy (01-12-2022)
    “…Different EGFR tyrosine kinase inhibitors (TKIs) have been developed for the treatment of non-small cell lung cancer (NSCLC) patients harboring sensitizing…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Lung Cancer Management with Silibinin: A Historical and Translational Perspective by Verdura, Sara, Cuyàs, Elisabet, Ruiz-Torres, Verónica, Micol, Vicente, Joven, Jorge, Bosch-Barrera, Joaquim, Menendez, Javier A.

    Published in Pharmaceuticals (Basel, Switzerland) (11-06-2021)
    “…The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin by Bosch-Barrera, Joaquim, Sais, Elia, Cañete, Noemí, Marruecos, Jordi, Cuyàs, Elisabet, Izquierdo, Angel, Porta, Rut, Haro, Manel, Brunet, Joan, Pedraza, Salvador, Menendez, Javier A

    Published in Oncotarget (31-05-2016)
    “…Despite multimodal treatment approaches, the prognosis of brain metastases (BM) from non-small cell lung cancer (NSCLC) remains poor. Untreated patients with…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin by Bosch-Barrera, Joaquim, Roqué, Ariadna, Teixidor, Eduard, Carmona-Garcia, Maria Carmen, Arbusà, Aina, Brunet, Joan, Martin-Castillo, Begoña, Cuyàs, Elisabet, Verdura, Sara, Menendez, Javier A

    Published in Pharmaceuticals (Basel, Switzerland) (24-12-2021)
    “…COVID-19 pathophysiology is caused by a cascade of respiratory and multiorgan failures arising, at least in part, from the SARS-CoV-2-driven dysregulation of…”
    Get full text
    Journal Article
  19. 19
  20. 20